Eli Lilly and Company (BKK:LLY80)

Market Cap	29.11T +24.1%
Revenue (ttm)	2.06T +44.7%
Net Income	650.92B +94.9%
EPS	723.77 +96.0%
Shares Out	n/a
PE Ratio	44.71
Forward PE	30.31
Dividend	0.01 (0.34%)
Ex-Dividend Date	Nov 14, 2025

Volume	1,735,088
Average Volume	6,894,284
Open	1.640
Previous Close	1.700
Day's Range	1.630 - 1.650
52-Week Range	1.010 - 1.830
Beta	n/a
RSI	48.91
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: LLY80

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD